Cangene

News Cangene

• Cangene and Barda extend botulism antitoxin contract

  Cangene Corporation reported that it has signed a no-cost modification to extend its botulism antitoxin contract with the Biomedical Advanced Research and Development Authority ("BARDA"). BARDA is the department within the U.S. Department of Health and Human Services ("HHS") that manages the two bio more

• Cangene acquires U.S. commercialization rights for HepaGam B from Apotex

  Cangene Corporation announced that it has signed an agreement with its majority shareholder, the Apotex Group, under which Cangene acquires all U.S. commercialization rights for HepaGam B(R) (Hepatitis B Immune Globulin Intravenous (Human)). HepaGam B(R) is Cangene's hepatitis B immune globulin, whi more

• Cangene acquires Twinstrand Therapeutics Inc.

  Cangene Corporation announces that it has acquired all issued and outstanding shares of privately held Twinstrand Therapeutics Inc. Cangene has paid $1.5 million (subject to post-closing adjustments) to acquire Twinstrand which has products, technologies and financial attributes including those rela more

Publications Cangene

• Functional Parsing of Driver Mutations in the Colorectal Cancer Genome Reveals Numerous Suppressors of Anchorage-Independent Growth

  Landmark cancer genome resequencing efforts are leading to the identification of mutated genes in many types of cancer. The extreme diversity of mutations being detected presents significant challenges to subdivide causal from coincidental mutations to elucidate how disrupted regulatory networks dri more

Market studies Cangene

• Burcon NutraScience Corporation (BU) - Financial and Strategic SWOT Analysis Review

  Burcon NutraScience Corporation (Burcon) is a research and development company. The company is engaged in the development of novel plant protein ingredients. Utilizing its patented technology, the company extracts protein isolates from soy and canola that have functional and beneficial nutritional a more

• Cangene Corporation (CNJ) - Financial and Strategic SWOT Analysis Review

  Cangene Corporation (Cangene) is a biopharmaceutical company. It is engaged in the development, manufacture, and marketing of specialty hyper immune plasma and biotechnology products. The flagship product of the company is WinRho. The services offered by the company fall into three main categories: more

Websites Cangene